MedTrace Logo

A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

NCT07172646 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-01-06

No results posted yet for this study

Summary

This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or without ASCVD history.

Conditions

  • Hyperlipoproteinemia (a)

Interventions

DRUG

SRSD216 injection

Administered SC.

DRUG

Placebo

Administered SC.

Sponsors & Collaborators

  • Sirius Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Director, MD · Sirius Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2026-05-31
Completion
2027-04-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07172646 on ClinicalTrials.gov